MDUFA Negotiations Mellow Out Over Opposing Wish Lists
This article was originally published in The Gray Sheet
Executive Summary
As FDA and industry struggle to align on reform priorities for a cost-conscious user-fee reauthorization proposal, the two sides took a step back to examine basic assumptions at a recent closed-door meeting.